Catapult Group International Ltd

CAT

Catapult Group International Ltd. engages in the development and supply of wearable athlete tracking and analytics solutions. The company is headquartered in Prahan, Victoria. The company went IPO on 2014-12-19. The Company’s products are designed to optimize performance, avoid injury, and improve return to play. The firm operates through three segments: Performance & Health, Tactics & Coaching and Media & Other. The Performance & Health segment is engaged in the design, development and supply of wearable technology and athlete monitoring software solutions to sports teams, athletes, and the prosumer market. The Tactics & Coaching segment is engaged in the design, development and supply of video analysis, editing, and publishing software solutions to sports teams. The Media & Other segment provides media licensing, athlete management and professional services to customers. Its wearable and video solutions are provided to elite clients on both a subscription and upfront capital sales basis. The firm works with more than 3,800 elite teams in over 40 sports.

De.Mem Limited

DEM

De.mem Ltd. operates as a holding company. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2017-04-07. The Company’s segment includes the Operations & Maintenance contracts segment, operates and maintains the clients’ water and wastewater treatment facilities; Build, Own, Operate (BOO) or Build, Own, Operate, Transfer (BOOT) services segment includes the equipment provided to the customer under a leasing scheme and operated and maintained by the Company under a long-term arrangement, and Specialty chemicals segment offers specialty chemicals required in water and wastewater treatment as well as in industrial processes, such as membrane cleaning agents, process chemicals and flocculants and coagulants. The firm is also engaged in the sale of pumps, small water treatment equipment and ongoing maintenance of the same.

ResMed Inc.

RMD

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. The company is headquartered in San Diego, California and currently employs 9,980 full-time employees. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. The company also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. The Company’s segments include Sleep and Respiratory Care and SaaS. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care to improve patient outcomes.

Superloop Limited

SLC

Superloop Ltd. engages in the provision of connectivity services in the Asia Pacific region. The company is headquartered in Sydney, New South Wales. The company went IPO on 2015-06-04. The firm operates through three segments: Wholesale, Business and Consumer. The Wholesale segment is defined by large scale telecommunications, data and technology customers who purchase various connectivity services to support their core business services, as well as retail Internet service providers who do not have access to a connectivity network of their own. The Business segment is defined by small, medium and large corporate customers who purchase connectivity services to facilitate their core business. The Consumer segment is defined by customers who purchase basic Internet and mobile phone products for domestic residential use. Its products include national broadband network (NBN) access, NBN TC2, NBN Enterprise Ethernet, dark fiber, fixed wireless access, third party access, security, managed Wi-Fi, international ethernet, wavelength and international (including Indigo) subsea cable capacity.

Bcal Diagnostics Limited

BDX

BCAL Diagnostics Ltd. develops screening tests for the early detection of breast cancer. The company is headquartered in Sydney, New South Wales. The company went IPO on 2021-07-21. The Company’s core activity is the development of a novel blood screening test to improve the early diagnosis and monitoring of breast cancer, which is available to all women. The company is developing diagnostic technology to assist in the early detection of breast cancer by identifying, measuring and validating specific biomarkers enriched in the patient’s blood. The company is engaged in the research and development of non-invasive diagnostic technologies designed to complement existing imaging technologies, such as the mammogram. Its BCAL laboratory employs liquid chromatography mass spectrometry (LCMS) platforms to build on the Company's clinical research and leverage progress. The Company’s BCAL test is a lipid biomarker blood (Breast Cancer Associated Lipids test) test with the potential to be used for breast cancer prevention, screening, and monitoring.